Answers are grounded in this paper and cite their sources.
We examined the real-world comparative safety of sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. other newer anti-glycemic medications (dipeptidyl peptidase-4 inhibitors [DPP4i], glucagon-like peptide-1 receptor agonists [GLP1a]) in patients with and without chronic kidney disease (CKD).
No takes yet. Share an insight, caveat, or question.
Narasaki et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: